

Specialty Drug List - Sorted by Drug Name
Developed for the Mississippi Division of Medicaid by Mercer

Published 2/1/2020

| Therapeutic Class | Drug Brand Name & Strength | Drug Generic Name | Effective Date |
|----------------------------|--------------------------------|---------------------------------|----------------|
| ANTI-INFECTIVE | ABELCET 100 MG/20 ML VIAL | amphotericin B lipid complex | 4/1/2017 |
| IMMUNE DEFICIENCY | ACTIMMUNE 100 MCG/0.5 ML VI | interferon gamma-1b,recomb. | 4/1/2017 |
| PULMONARY HYPERTENSION | ADEMPAS 0.5 MG TABLET | riociguat | 4/1/2017 |
| PULMONARY HYPERTENSION | ADEMPAS 1 MG TABLET | riociguat | 4/1/2017 |
| PULMONARY HYPERTENSION | ADEMPAS 1.5 MG TABLET | riociguat | 4/1/2017 |
| PULMONARY HYPERTENSION | ADEMPAS 2 MG TABLET | riociguat | 4/1/2017 |
| PULMONARY HYPERTENSION | ADEMPAS 2.5 MG TABLET | riociguat | 4/1/2017 |
| ONCOLOGY - ORAL | AFINITOR 10 MG TABLET | everolimus | 4/1/2017 |
| ONCOLOGY - ORAL | AFINITOR 2.5 MG TABLET | everolimus | 4/1/2017 |
| ONCOLOGY - ORAL | AFINITOR 5 MG TABLET | everolimus | 4/1/2017 |
| ONCOLOGY - ORAL | AFINITOR 7.5 MG TABLET | everolimus | 4/1/2017 |
| ONCOLOGY - ORAL | AFINITOR DISPERZ 2 MG TABLET | everolimus | 4/1/2017 |
| ONCOLOGY - ORAL | AFINITOR DISPERZ 3 MG TABLET | everolimus | 4/1/2017 |
| ONCOLOGY - ORAL | AFINITOR DISPERZ 5 MG TABLET | everolimus | 4/1/2017 |
| ONCOLOGY - ORAL | ALECENSA 150 MG CAPSULE | alectinib HCl | 4/1/2017 |
| ONCOLOGY - ORAL | ALKERAN 2 MG TABLET | melphalan | 4/1/2017 |
| ONCOLOGY - ORAL | ALUNBRIG 180 MG TABLET | brigatinib | 3/1/2018 |
| ONCOLOGY - ORAL | ALUNBRIG 30 MG TABLET | brigatinib | 4/1/2017 |
| ONCOLOGY - ORAL | ALUNBRIG 90 MG TABLET | brigatinib | 3/1/2018 |
| ONCOLOGY - ORAL | ALUNBRIG 90 MG-180 MG TAB PACK | brigatinib | 3/1/2018 |
| ANTI-INFECTIVE | AMBISOME 50 MG VIAL | amphotericin B liposome | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | AMIFOSTINE 500 MG VIAL | amifostine crystalline | 4/1/2017 |
| ENZYME DEFICIENCY | AMMONUL 10%-10% VIAL | sodium benzoate/sod phenylacet | 4/1/2017 |
| ANTI-INFECTIVE | ANCOBON 250 MG CAPSULE | flucytosine | 4/1/2017 |
| ANTI-INFECTIVE | ANCOBON 500 MG CAPSULE | flucytosine | 4/1/2017 |
| OTHER SPECIALTY CONDITION | APOKYN 30 MG/3 ML CARTRIDGE | apomorphine HCl | 4/1/2017 |
| PULMONARY | ARALAST NP 500 MG VIAL | alpha-1-proteinase inhibitor | 4/1/2017 |
| OTHER SPECIALTY CONDITION | ARCALYST 220 MG INJECTION | rilonacept | 4/1/2017 |
| PULMONARY | ARIKAYCE 590 MG/8.4 ML VIAL | amikacin liposomal/neb.accesssr | 2/1/2019 |
| ANTI-INFECTIVE | AVYCAZ 2.5 GRAM VIAL | ceftazidime/avibactam | 4/1/2017 |
| ONCOLOGY - ORAL | BALVERSA 3 MG TABLET | erdafitinib | 6/1/2019 |
| ONCOLOGY - ORAL | BALVERSA 4 MG TABLET | erdafitinib | 6/1/2019 |
| ONCOLOGY - ORAL | BALVERSA 5 MG TABLET | erdafitinib | 6/1/2019 |
| OTHER SPECIALTY CONDITION | BENLYSTA 200 MG/ML AUTOINJECT | belimumab | 10/1/2017 |
| OTHER SPECIALTY CONDITION | BENLYSTA 200 MG/ML SYRINGE | belimumab | 10/1/2017 |
| HEREDITARY ANGIOEDEMA | BERINERT 500 UNIT KIT | C1 esterase inhibitor | 4/1/2017 |
| PULMONARY | BETHKIS 300 MG/4 ML AMPULE | tobramycin | 4/1/2017 |
| IMMUNE DEFICIENCY | BIVIGAM LIQUID 10% VIAL | immun glob G(IgG)/gly/IgA ov50 | 4/1/2017 |
| ONCOLOGY - ORAL | BOSULIF 100 MG TABLET | bosutinib | 4/1/2017 |
| ONCOLOGY - ORAL | BOSULIF 400 MG TABLET | bosutinib | 2/1/2018 |
| ONCOLOGY - ORAL | BOSULIF 500 MG TABLET | bosutinib | 4/1/2017 |
| OTHER SPECIALTY CONDITION | BUPHENYL 500 MG TABLET | sodium phenylbutyrate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | CABLIVI 11 MG KIT | caplacizumab-yhdp | 5/1/2019 |
| ONCOLOGY - ORAL | CABOMETYX 20 MG TABLET | cabozantinib s-malate | 4/1/2017 |
| ONCOLOGY - ORAL | CABOMETYX 40 MG TABLET | cabozantinib s-malate | 4/1/2017 |
| ONCOLOGY - ORAL | CABOMETYX 60 MG TABLET | cabozantinib s-malate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | CALCITRIOL 1 MCG/ML AMPUL | calcitriol | 4/1/2017 |
| ONCOLOGY - ORAL | CALQUENCE 100 MG CAPSULE | acalabrutinib | 1/1/2018 |
| ONCOLOGY - ORAL | CAPRELSA 100 MG TABLET | vandetanib | 4/1/2017 |
| ONCOLOGY - ORAL | CAPRELSA 300 MG TABLET | vandetanib | 4/1/2017 |
| ENZYME DEFICIENCY | CARBAGLU 200 MG DISPER TABL | carglumic acid | 4/1/2017 |
| IMMUNE DEFICIENCY | CARIMUNE NF 12 GM VIAL | immun globG(IgG)/sucr/IgA ov50 | 4/1/2017 |
| IMMUNE DEFICIENCY | CARIMUNE NF 6 GM VIAL | immun globG(IgG)/sucr/IgA ov50 | 4/1/2017 |
| PULMONARY | CAYSTON 75 MG INHAL SOLUTIO | aztreonam lysine | 4/1/2017 |
| OTHER SPECIALTY CONDITION | CEPROTIN 400-600 UNITS VIAL | protein C, human | 4/1/2017 |
| OTHER SPECIALTY CONDITION | CEPROTIN 800-1,200 UNITS VI | protein C, human | 4/1/2017 |
| ENZYME DEFICIENCY | CERDELGA 84 MG CAPSULE | eliglustat tartrate | 4/1/2017 |

Specialty Drug List - Sorted by Drug Name
Developed for the Mississippi Division of Medicaid by Mercer

| Therapeutic Class | Drug Brand Name & Strength | Drug Generic Name | Effective Date |
|---------------------------|-------------------------------|--------------------------------|----------------|
| ENZYME DEFICIENCY | CEREZYME 400 UNITS VIAL | imiglucerase | 4/1/2017 |
| OTHER SPECIALTY CONDITION | CHENODAL 250 MG TABLET | chenodiol | 4/1/2017 |
| OTHER SPECIALTY CONDITION | CHOLBAM 250 MG CAPSULE | cholic acid | 4/1/2017 |
| OTHER SPECIALTY CONDITION | CHOLBAM 50 MG CAPSULE | cholic acid | 4/1/2017 |
| HEREDITARY ANGIOEDEMA | CINRYZE 500 UNIT VIAL | C1 esterase inhibitor | 4/1/2017 |
| ONCOLOGY - ORAL | COMETRIQ 100 MG DAILY-DOSE | cabozantinib s-malate | 4/1/2017 |
| ONCOLOGY - ORAL | COMETRIQ 140 MG DAILY-DOSE | cabozantinib s-malate | 4/1/2017 |
| ONCOLOGY - ORAL | COMETRIQ 60 MG DAILY-DOSE P | cabozantinib s-malate | 4/1/2017 |
| ONCOLOGY - ORAL | COPIKTRA 15 MG CAPSULE | duvelisib | 1/1/2019 |
| ONCOLOGY - ORAL | COPIKTRA 25 MG CAPSULE | duvelisib | 1/1/2019 |
| ONCOLOGY - ORAL | COTELLIC 20 MG TABLET | cobimetinib fumarate | 4/1/2017 |
| ANTI-INFECTIVE | CRESEMBA 372 MG VIAL | isavuconazonium sulfate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | CRYSVITA 10 MG/ML VIAL | burosumab-twza | 7/1/2018 |
| OTHER SPECIALTY CONDITION | CRYSVITA 20 MG/ML VIAL | burosumab-twza | 7/1/2018 |
| OTHER SPECIALTY CONDITION | CRYSVITA 30 MG/ML VIAL | burosumab-twza | 7/1/2018 |
| IMMUNE DEFICIENCY | CUVITRU 1 GRAM/5 ML VIAL | immun glob G(IgG)/gly/IgA ov50 | 4/1/2017 |
| IMMUNE DEFICIENCY | CUVITRU 10 GRAM/50 ML VIAL | immun glob G(IgG)/gly/IgA ov50 | 10/1/2019 |
| IMMUNE DEFICIENCY | CUVITRU 2 GRAM/10 ML VIAL | immun glob G(IgG)/gly/IgA ov50 | 4/1/2017 |
| IMMUNE DEFICIENCY | CUVITRU 4 GRAM/20 ML VIAL | immun glob G(IgG)/gly/IgA ov50 | 4/1/2017 |
| IMMUNE DEFICIENCY | CUVITRU 8 GRAM/ 40 ML VIAL | immun glob G(IgG)/gly/IgA ov50 | 4/1/2017 |
| OTHER SPECIALTY CONDITION | CYSTAGON 150 MG CAPSULE | cysteamine bitartrate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | CYSTAGON 50 MG CAPSULE | cysteamine bitartrate | 4/1/2017 |
| IMMUNE DEFICIENCY | CYTOGAM 2.5 GM/50 ML VIAL | cytomegalovirus immune globuln | 4/1/2017 |
| ANTI-INFECTIVE | DALVANCE 500 MG VIAL | dalbavancin HCl | 4/1/2017 |
| ANTI-INFECTIVE | DAPTOMYCIN 350 MG VIAL | daptomycin | 12/1/2019 |
| ANTI-INFECTIVE | DAPTOMYCIN 500 MG VIAL | daptomycin | 4/1/2017 |
| ONCOLOGY - ORAL | DAURISMO 100 MG TABLET | glasdegib maleate | 3/1/2019 |
| ONCOLOGY - ORAL | DAURISMO 25 MG TABLET | glasdegib maleate | 3/1/2019 |
| OTHER SPECIALTY CONDITION | DEFERAL 2 GRAM VIAL | deferoxamine mesylate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | DEFERAL MESYLATE 500 MG VL | deferoxamine mesylate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | DILUENT FOR FLOLAN VIAL | diluent for epoprostenol(glyc) | 4/1/2017 |
| OTHER SPECIALTY CONDITION | DUOPA 4.63 MG-20 MG/ML SUSP | carbidopa/levodopa | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EGRIFTA 1 MG VIAL | tesamorelin acetate | 4/1/2017 |
| ENZYME DEFICIENCY | ELELYSO 200 UNITS VIAL | taliglucerase alfa | 4/1/2017 |
| ONCOLOGY - ORAL | EMCYT 140 MG CAPSULE | estramustine phosphate sodium | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EMFLAZA 18 MG TABLET | deflazacort | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EMFLAZA 22.75 MG/ML ORAL SUSP | deflazacort | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EMFLAZA 30 MG TABLET | deflazacort | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EMFLAZA 36 MG TABLET | deflazacort | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EMFLAZA 6 MG TABLET | deflazacort | 4/1/2017 |
| OTHER SPECIALTY CONDITION | ENDARI 5 GRAM POWDER PACKET | glutamine | 4/1/2018 |
| ONCOLOGY - ORAL | ERIVEDGE 150 MG CAPSULE | vismodegib | 4/1/2017 |
| ONCOLOGY - ORAL | ERLEADA 60 MG TABLET | apalutamide | 4/1/2018 |
| PULMONARY | ESBRIET 267 MG CAPSULE | pirfenidone | 4/1/2017 |
| PULMONARY | ESBRIET 267 MG TABLET | pirfenidone | 4/1/2017 |
| PULMONARY | ESBRIET 801 MG TABLET | pirfenidone | 4/1/2017 |
| ONCOLOGY - ORAL | ETOPOSIDE 50 MG CAPSULE | etoposide | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EXJADE 125 MG TABLET | deferasirox | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EXJADE 250 MG TABLET | deferasirox | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EXJADE 500 MG TABLET | deferasirox | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EXONDYS 51 100 MG/2 ML VIAL | eteplirsen | 4/1/2017 |
| OTHER SPECIALTY CONDITION | EXONDYS 51 500 MG/10 ML VIA | eteplirsen | 4/1/2017 |
| ENZYME DEFICIENCY | FABRAZYME 35 MG VIAL | agalsidase beta | 4/1/2017 |
| ENZYME DEFICIENCY | FABRAZYME 5 MG VIAL | agalsidase beta | 4/1/2017 |
| ONCOLOGY - ORAL | FARYDAK 10 MG CAPSULE | panobinostat lactate | 4/1/2017 |
| ONCOLOGY - ORAL | FARYDAK 15 MG CAPSULE | panobinostat lactate | 4/1/2017 |
| ONCOLOGY - ORAL | FARYDAK 20 MG CAPSULE | panobinostat lactate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | FERRIPROX 1,000 MG TABLET | deferiprone | 10/1/2019 |

Specialty Drug List - Sorted by Drug Name
Developed for the Mississippi Division of Medicaid by Mercer

| Therapeutic Class | Drug Brand Name & Strength | Drug Generic Name | Effective Date |
|----------------------------|-----------------------------|--------------------------------|----------------|
| OTHER SPECIALTY CONDITION | FERRIPROX 100 MG/ML SOLUTIO | deferiprone | 4/1/2017 |
| OTHER SPECIALTY CONDITION | FERRIPROX 500 MG TABLET | deferiprone | 4/1/2017 |
| HEREDITARY ANGIOEDEMA | FIRAZYR 30 MG/3 ML SYRINGE | icatibant acetate | 4/1/2017 |
| IMMUNE DEFICIENCY | FLEBOGAMMA DIF 10% VIAL | imm glob G (IgG)/sorb/IgA 0-50 | 4/1/2017 |
| IMMUNE DEFICIENCY | FLEBOGAMMA DIF 5% VIAL | imm glob G (IgG)/sorb/IgA 0-50 | 4/1/2017 |
| PULMONARY HYPERTENSION | FLOLAN 0.5 MG VIAL | epoprostenol sodium (glycine) | 4/1/2017 |
| PULMONARY HYPERTENSION | FLOLAN 1.5 MG VIAL | epoprostenol sodium (glycine) | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | FUSILEV I.V. 50 MG VIAL | levoleucovorin calcium | 4/1/2017 |
| OTHER SPECIALTY CONDITION | GABLOFEN 10,000 MCG/20 ML S | baclofen | 4/1/2017 |
| OTHER SPECIALTY CONDITION | GABLOFEN 10,000 MCG/20 ML V | baclofen | 4/1/2017 |
| OTHER SPECIALTY CONDITION | GABLOFEN 20,000 MCG/20 ML S | baclofen | 4/1/2017 |
| OTHER SPECIALTY CONDITION | GABLOFEN 20,000 MCG/20 ML V | baclofen | 4/1/2017 |
| OTHER SPECIALTY CONDITION | GABLOFEN 40,000 MCG/20 ML S | baclofen | 4/1/2017 |
| OTHER SPECIALTY CONDITION | GABLOFEN 40,000 MCG/20 ML V | baclofen | 4/1/2017 |
| ENZYME DEFICIENCY | GALAFOLD 123 MG CAPSULE | migalastat HCl | 10/1/2018 |
| IMMUNE DEFICIENCY | GAMMAGARD LIQUID 10% VIAL | immun glob G(IgG)/gly/IgA ov50 | 4/1/2017 |
| IMMUNE DEFICIENCY | GAMMAGARD S-D 10 G (IGA<1) | immun glob G/gly/gluc/IgA 0-50 | 4/1/2017 |
| IMMUNE DEFICIENCY | GAMMAGARD S-D 5 G (IGA<1) S | immun glob G/gly/gluc/IgA 0-50 | 4/1/2017 |
| IMMUNE DEFICIENCY | GAMMAPLEX 5 GRAM/50 ML VIAL | immun glob G(IgG)/gly/IgA 0-50 | 4/1/2017 |
| IMMUNE DEFICIENCY | GAMMAPLEX 5% VIAL | immun glob G/sorb/gly/IgA 0-50 | 4/1/2017 |
| IMMUNE DEFICIENCY | GAMUNEX-C 1 GRAM/10 ML VIAL | immune globul G/gly/IgA avg 46 | 4/1/2017 |
| IMMUNE DEFICIENCY | GAMUNEX-C 10 GRAM/100 ML VI | immune globul G/gly/IgA avg 46 | 4/1/2017 |
| IMMUNE DEFICIENCY | GAMUNEX-C 2.5 GRAM/25 ML VI | immune globul G/gly/IgA avg 46 | 4/1/2017 |
| IMMUNE DEFICIENCY | GAMUNEX-C 20 GRAM/200 ML VI | immune globul G/gly/IgA avg 46 | 4/1/2017 |
| IMMUNE DEFICIENCY | GAMUNEX-C 40 GRAM/400 ML VI | immune globul G/gly/IgA avg 46 | 4/1/2017 |
| IMMUNE DEFICIENCY | GAMUNEX-C 5 GRAM/50 ML VIAL | immune globul G/gly/IgA avg 46 | 4/1/2017 |
| OTHER SPECIALTY CONDITION | GATTEX 5 MG 30-VIAL KIT | teduglutide | 4/1/2017 |
| ONCOLOGY - ORAL | GILOTRIF 20 MG TABLET | afatinib dimaleate | 4/1/2017 |
| ONCOLOGY - ORAL | GILOTRIF 30 MG TABLET | afatinib dimaleate | 4/1/2017 |
| ONCOLOGY - ORAL | GILOTRIF 40 MG TABLET | afatinib dimaleate | 4/1/2017 |
| PULMONARY | GLASSIA 1 GM/50 ML VIAL | alpha-1-proteinase inhibitor | 4/1/2017 |
| HEREDITARY ANGIOEDEMA | HAEGARDA 2,000 UNIT VIAL | C1 esterase inhibitor | 10/1/2017 |
| HEREDITARY ANGIOEDEMA | HAEGARDA 3,000 UNIT VIAL | C1 esterase inhibitor | 10/1/2017 |
| OTHER SPECIALTY CONDITION | HEMLIBRA 105 MG/0.7 VIAL | emicizumab-kxwh | 11/16/2017 |
| OTHER SPECIALTY CONDITION | HEMLIBRA 150 MG/ML VIAL | emicizumab-kxwh | 11/16/2017 |
| OTHER SPECIALTY CONDITION | HEMLIBRA 30 MG/ML VIAL | emicizumab-kxwh | 11/16/2017 |
| OTHER SPECIALTY CONDITION | HEMLIBRA 60MG/0.4ML VIAL | emicizumab-kxwh | 11/16/2017 |
| OTHER SPECIALTY CONDITION | HETLIOZ 20 MG CAPSULE | tasimelteon | 4/1/2017 |
| IMMUNE DEFICIENCY | HIZENTRA 1 GRAM/5 ML VIAL | immun glob G(IgG)/pro/IgA 0-50 | 4/1/2017 |
| IMMUNE DEFICIENCY | HIZENTRA 10 GRAM/50 ML VIAL | immun glob G(IgG)/pro/IgA 0-50 | 4/1/2017 |
| IMMUNE DEFICIENCY | HIZENTRA 2 GRAM/10 ML VIAL | immun glob G(IgG)/pro/IgA 0-50 | 4/1/2017 |
| IMMUNE DEFICIENCY | HIZENTRA 4 GRAM/20 ML VIAL | immun glob G(IgG)/pro/IgA 0-50 | 4/1/2017 |
| OTHER SPECIALTY CONDITION | HP ACTHAR GEL 80 UNIT/ML VI | corticotropin | 4/1/2017 |
| ONCOLOGY - ORAL | HYCANTIN 0.25 MG CAPSULE | topotecan HCl | 4/1/2017 |
| ONCOLOGY - ORAL | HYCANTIN 1 MG CAPSULE | topotecan HCl | 4/1/2017 |
| IMMUNE DEFICIENCY | HYQVIA 10 GM-800 UNIT PACK | IgG/hyaluronidase,recombinant | 4/1/2017 |
| IMMUNE DEFICIENCY | HYQVIA 2.5 GM-200 UNIT PACK | IgG/hyaluronidase,recombinant | 4/1/2017 |
| IMMUNE DEFICIENCY | HYQVIA 20 GM-1,600 UNIT PAC | IgG/hyaluronidase,recombinant | 4/1/2017 |
| IMMUNE DEFICIENCY | HYQVIA 30 GM-2,400 UNIT PAC | IgG/hyaluronidase,recombinant | 4/1/2017 |
| IMMUNE DEFICIENCY | HYQVIA 5 GM-400 UNIT PACK | IgG/hyaluronidase,recombinant | 4/1/2017 |
| ONCOLOGY - ORAL | IBRANCE 100 MG CAPSULE | palbociclib | 4/1/2017 |
| ONCOLOGY - ORAL | IBRANCE 125 MG CAPSULE | palbociclib | 4/1/2017 |
| ONCOLOGY - ORAL | IBRANCE 75 MG CAPSULE | palbociclib | 4/1/2017 |
| ONCOLOGY - ORAL | ICLUSIG 15 MG TABLET | ponatinib HCl | 4/1/2017 |
| ONCOLOGY - ORAL | ICLUSIG 45 MG TABLET | ponatinib HCl | 4/1/2017 |
| ONCOLOGY - ORAL | IDHIFA 100 MG TABLET | enasidenib mesylate | 10/1/2017 |
| ONCOLOGY - ORAL | IDHIFA 50 MG TABLET | enasidenib mesylate | 10/1/2017 |
| ONCOLOGY - ORAL | IMBRUVICA 140 MG CAPSULE | ibrutinib | 4/1/2017 |

Specialty Drug List - Sorted by Drug Name
Developed for the Mississippi Division of Medicaid by Mercer

| Therapeutic Class | Drug Brand Name & Strength | Drug Generic Name | Effective Date |
|----------------------------|--------------------------------|--------------------------------|----------------|
| ONCOLOGY - ORAL | IMBRUVICA 140 MG TABLET | ibrutinib | 5/1/2018 |
| ONCOLOGY - ORAL | IMBRUVICA 280 MG TABLET | ibrutinib | 5/1/2018 |
| ONCOLOGY - ORAL | IMBRUVICA 420 MG TABLET | ibrutinib | 5/1/2018 |
| ONCOLOGY - ORAL | IMBRUVICA 560 MG TABLET | ibrutinib | 5/1/2018 |
| ONCOLOGY - ORAL | IMBRUVICA 70 MG CAPSULE | ibrutinib | 5/1/2018 |
| OTHER SPECIALTY CONDITION | INCRELEX 40 MG/4 ML VIAL | mecasermin | 4/1/2017 |
| ONCOLOGY - ORAL | INLYTA 1 MG TABLET | axitinib | 4/1/2017 |
| ONCOLOGY - ORAL | INLYTA 5 MG TABLET | axitinib | 4/1/2017 |
| ONCOLOGY - ORAL | INREBIC 100 MG CAPSULE | fedratinib dihydrochloride | 10/1/2019 |
| ONCOLOGY - ORAL | IRESSA 250 MG TABLET | gefitinib | 4/1/2017 |
| OTHER SPECIALTY CONDITION | JADENU 180 MG TABLET | deferasirox | 4/1/2017 |
| OTHER SPECIALTY CONDITION | JADENU 360 MG TABLET | deferasirox | 4/1/2017 |
| OTHER SPECIALTY CONDITION | JADENU 90 MG TABLET | deferasirox | 4/1/2017 |
| OTHER SPECIALTY CONDITION | JADENU SPRINKLE 180 MG GRANULE | deferasirox | 10/1/2017 |
| OTHER SPECIALTY CONDITION | JADENU SPRINKLE 360 MG GRANULE | deferasirox | 10/1/2017 |
| OTHER SPECIALTY CONDITION | JADENU SPRINKLE 90 MG GRANULE | deferasirox | 10/1/2017 |
| ONCOLOGY - ORAL | JAKAFI 10 MG TABLET | ruxolitinib phosphate | 4/1/2017 |
| ONCOLOGY - ORAL | JAKAFI 15 MG TABLET | ruxolitinib phosphate | 4/1/2017 |
| ONCOLOGY - ORAL | JAKAFI 20 MG TABLET | ruxolitinib phosphate | 4/1/2017 |
| ONCOLOGY - ORAL | JAKAFI 25 MG TABLET | ruxolitinib phosphate | 4/1/2017 |
| ONCOLOGY - ORAL | JAKAFI 5 MG TABLET | ruxolitinib phosphate | 4/1/2017 |
| HIGH CHOLESTEROL | JUXTAPID 10 MG CAPSULE | lomitapide mesylate | 4/1/2017 |
| HIGH CHOLESTEROL | JUXTAPID 20 MG CAPSULE | lomitapide mesylate | 4/1/2017 |
| HIGH CHOLESTEROL | JUXTAPID 30 MG CAPSULE | lomitapide mesylate | 4/1/2017 |
| HIGH CHOLESTEROL | JUXTAPID 40 MG CAPSULE | lomitapide mesylate | 4/1/2017 |
| HIGH CHOLESTEROL | JUXTAPID 5 MG CAPSULE | lomitapide mesylate | 4/1/2017 |
| HIGH CHOLESTEROL | JUXTAPID 60 MG CAPSULE | lomitapide mesylate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | JYNARQUE 45 MG-15 MG TABLET | tolvaptan | 7/1/2018 |
| OTHER SPECIALTY CONDITION | JYNARQUE 60 MG-30 MG TABLET | tolvaptan | 7/1/2018 |
| OTHER SPECIALTY CONDITION | JYNARQUE 90 MG-30 MG TABLET | tolvaptan | 7/1/2018 |
| HEREDITARY ANGIOEDEMA | KALBITOR 10 MG/ML VIAL | ecallantide | 4/1/2017 |
| PULMONARY | KALYDECO 150 MG TABLET | ivacaftor | 4/1/2017 |
| PULMONARY | KALYDECO 25 MG GRANULES PACKET | ivacaftor | 7/1/2019 |
| PULMONARY | KALYDECO 50 MG GRANULES PAC | ivacaftor | 4/1/2017 |
| PULMONARY | KALYDECO 75 MG GRANULES PAC | ivacaftor | 4/1/2017 |
| ENZYME DEFICIENCY | KANUMA 20 MG/10 ML VIAL | sebelipase alfa | 4/1/2017 |
| OTHER SPECIALTY CONDITION | KEVEYIS 50 MG TABLET | dichlorphenamide | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | KHAPZORY 175 MG VIAL | levoleucovorin | 3/1/2019 |
| ONCOLOGY - ADJUNCT THERAPY | KHAPZORY 300 MG VIAL | levoleucovorin | 3/1/2019 |
| ONCOLOGY - ORAL | KISQALI 200 MG DAILY DOSE | ribociclib succinate | 4/1/2017 |
| ONCOLOGY - ORAL | KISQALI 400 MG DAILY DOSE | ribociclib succinate | 4/1/2017 |
| ONCOLOGY - ORAL | KISQALI 600 MG DAILY DOSE | ribociclib succinate | 4/1/2017 |
| ONCOLOGY - ORAL | KISQALI FEMARA 200 MG CO-PACK | ribociclib succinate/letrozole | 4/1/2017 |
| ONCOLOGY - ORAL | KISQALI FEMARA 400 MG CO-PACK | ribociclib succinate/letrozole | 4/1/2017 |
| ONCOLOGY - ORAL | KISQALI FEMARA 600 MG CO-PACK | ribociclib succinate/letrozole | 4/1/2017 |
| PULMONARY | KITABIS PAK 300 MG/5 ML | tobramycin/nebulizer | 4/1/2017 |
| OTHER SPECIALTY CONDITION | KORLYM 300 MG TABLET | mifepristone | 4/1/2017 |
| ENZYME DEFICIENCY | KUVAN 100 MG POWDER PACKET | sapropterin dihydrochloride | 4/1/2017 |
| ENZYME DEFICIENCY | KUVAN 100 MG TABLET | sapropterin dihydrochloride | 4/1/2017 |
| ENZYME DEFICIENCY | KUVAN 500 MG POWDER PACKET | sapropterin dihydrochloride | 4/1/2017 |
| ONCOLOGY - ORAL | LENVIMA 10 MG DAILY DOSE | lenvatinib mesylate | 4/1/2017 |
| ONCOLOGY - ORAL | LENVIMA 12 MG DAILY DOSE | lenvatinib mesylate | 10/1/2018 |
| ONCOLOGY - ORAL | LENVIMA 14 MG DAILY DOSE | lenvatinib mesylate | 4/1/2017 |
| ONCOLOGY - ORAL | LENVIMA 18 MG DAILY DOSE | lenvatinib mesylate | 4/1/2017 |
| ONCOLOGY - ORAL | LENVIMA 20 MG DAILY DOSE | lenvatinib mesylate | 4/1/2017 |
| ONCOLOGY - ORAL | LENVIMA 24 MG DAILY DOSE | lenvatinib mesylate | 4/1/2017 |
| ONCOLOGY - ORAL | LENVIMA 4 MG CAPSULE | lenvatinib mesylate | 10/1/2018 |
| ONCOLOGY - ORAL | LENVIMA 8 MG DAILY DOSE | lenvatinib mesylate | 4/1/2017 |

Specialty Drug List - Sorted by Drug Name
Developed for the Mississippi Division of Medicaid by Mercer

| Therapeutic Class | Drug Brand Name & Strength | Drug Generic Name | Effective Date |
|----------------------------|--------------------------------|--------------------------------|----------------|
| PULMONARY HYPERTENSION | LETAIRIS 10 MG TABLET | ambrisentan | 4/1/2017 |
| PULMONARY HYPERTENSION | LETAIRIS 5 MG TABLET | ambrisentan | 4/1/2017 |
| BLOOD CELL DEFICIENCY | LEUKINE 250 MCG VIAL | sargramostim | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | LEVOLEUCOVORIN 175 MG/17.5 | levoleucovorin calcium | 4/1/2017 |
| OTHER SPECIALTY CONDITION | LIORESAL IT 10 MG/20 ML KIT | baclofen | 4/1/2017 |
| OTHER SPECIALTY CONDITION | LIORESAL IT 10 MG/5 ML KIT | baclofen | 4/1/2017 |
| ONCOLOGY - ORAL | LONSURF 15 MG-6.14 MG TABLET | trifluridine/tipiracil HCl | 4/1/2017 |
| ONCOLOGY - ORAL | LONSURF 20 MG-8.19 MG TABLET | trifluridine/tipiracil HCl | 4/1/2017 |
| ONCOLOGY - ORAL | LORBRENA 100 MG TABLET | lorlatinib | 1/1/2019 |
| ONCOLOGY - ORAL | LORBRENA 25 MG TABLET | lorlatinib | 1/1/2019 |
| ENZYME DEFICIENCY | LUMIZYME 50 MG VIAL | alglucosidase alfa | 4/1/2017 |
| OTHER SPECIALTY CONDITION | LUPANETA PK 11.25-5 MG 3MO | leuprolide/norethindrone acet | 4/1/2017 |
| OTHER SPECIALTY CONDITION | LUPANETA PK 3.75-5 MG 1MO K | leuprolide/norethindrone acet | 4/1/2017 |
| OTHER SPECIALTY CONDITION | LUPRON DEPOT-PED 11.25 MG 3 | leuprolide acetate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | LUPRON DEPOT-PED 11.25 MG K | leuprolide acetate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | LUPRON DEPOT-PED 15 MG KIT | leuprolide acetate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | LUPRON DEPOT-PED 30 MG 3MO | leuprolide acetate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | LUPRON DEPOT-PED 7.5 MG KIT | leuprolide acetate | 4/1/2017 |
| ONCOLOGY - ORAL | LYNPARZA 100 MG TABLET | olaparib | 10/1/2017 |
| ONCOLOGY - ORAL | LYNPARZA 150 MG TABLET | olaparib | 10/1/2017 |
| ONCOLOGY - ORAL | LYNPARZA 50 MG CAPSULE | olaparib | 4/1/2017 |
| ONCOLOGY - ORAL | LYSODREN 500 MG TABLET | mitotane | 4/1/2017 |
| OTHER SPECIALTY CONDITION | MAKENA 1,250 MG/5 ML VIAL | hydroxyprogesterone caproate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | MAKENA 250 MG/ML VIAL | hydroxyprogesterone caproat/PF | 4/1/2017 |
| OTHER SPECIALTY CONDITION | MAKENA 275 MG/1.1 ML AUTOINJCT | hydroxyprogesterone caproat/PF | 5/1/2018 |
| ONCOLOGY - ORAL | MATULANE 50 MG CAPSULE | procarbazine HCl | 4/1/2017 |
| ONCOLOGY - ORAL | MEKINIST 0.5 MG TABLET | trametinib dimethyl sulfoxide | 4/1/2017 |
| ONCOLOGY - ORAL | MEKINIST 2 MG TABLET | trametinib dimethyl sulfoxide | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | MESNEX 1 GRAM/10 ML VIAL | mesna | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | MESNEX 400 MG TABLET | mesna | 4/1/2017 |
| BLOOD CELL DEFICIENCY | MULPLETA 3 MG TABLET | lusutrombopag | 10/1/2018 |
| ENDOCRINE DISORDER | MYALEPT 11.3 MG (5 MG/ML) VIAL | metreleptin | 7/1/2018 |
| ONCOLOGY - ORAL | MYLERAN 2 MG TABLET | busulfan | 4/1/2017 |
| OTHER SPECIALTY CONDITION | NATPARA 100 MCG DOSE CARTRI | parathyroid hormone | 4/1/2017 |
| OTHER SPECIALTY CONDITION | NATPARA 25 MCG DOSE CARTRID | parathyroid hormone | 4/1/2017 |
| OTHER SPECIALTY CONDITION | NATPARA 50 MCG DOSE CARTRID | parathyroid hormone | 4/1/2017 |
| OTHER SPECIALTY CONDITION | NATPARA 75 MCG DOSE CARTRID | parathyroid hormone | 4/1/2017 |
| ONCOLOGY - ORAL | NERLYNX 40 MG TABLET | neratinib maleate | 2/1/2018 |
| ONCOLOGY - ORAL | NEXAVAR 200 MG TABLET | sorafenib tosylate | 4/1/2017 |
| ONCOLOGY - ORAL | NILANDRON 150 MG TABLET | nilutamide | 4/1/2017 |
| ONCOLOGY - ORAL | NINLARO 2.3 MG CAPSULE | ixazomib citrate | 4/1/2017 |
| ONCOLOGY - ORAL | NINLARO 3 MG CAPSULE | ixazomib citrate | 4/1/2017 |
| ONCOLOGY - ORAL | NINLARO 4 MG CAPSULE | ixazomib citrate | 4/1/2017 |
| ENZYME DEFICIENCY | NITYR 10 MG TABLET | nitisinone | 10/1/2017 |
| ENZYME DEFICIENCY | NITYR 2 MG TABLET | nitisinone | 10/1/2017 |
| ENZYME DEFICIENCY | NITYR 5 MG TABLET | nitisinone | 10/1/2017 |
| OTHER SPECIALTY CONDITION | NORTHERA 100 MG CAPSULE | droxidopa | 4/1/2017 |
| OTHER SPECIALTY CONDITION | NORTHERA 200 MG CAPSULE | droxidopa | 4/1/2017 |
| OTHER SPECIALTY CONDITION | NORTHERA 300 MG CAPSULE | droxidopa | 4/1/2017 |
| BLOOD CELL DEFICIENCY | NPLATE 125 MCG VIAL | romiplostim | 1/1/2020 |
| BLOOD CELL DEFICIENCY | NPLATE 250 MCG VIAL | romiplostim | 4/1/2017 |
| BLOOD CELL DEFICIENCY | NPLATE 500 MCG VIAL | romiplostim | 4/1/2017 |
| ONCOLOGY - ORAL | NUBEQA 300 MG TABLET | darolutamide | 10/1/2019 |
| OTHER SPECIALTY CONDITION | NYMALIZE 60 MG/20 ML SOLUTI | nimodipine | 4/1/2017 |
| OTHER SPECIALTY CONDITION | NYMALIZE 60 MG/20 ML SOLUTI | nimodipine | 4/1/2017 |
| OTHER SPECIALTY CONDITION | NYMALIZE 60 MG/20 ML SOLUTION | nimodipine | 11/1/2017 |
| OTHER SPECIALTY CONDITION | OCALIVA 10 MG TABLET | obeticholic acid | 4/1/2017 |
| OTHER SPECIALTY CONDITION | OCALIVA 5 MG TABLET | obeticholic acid | 4/1/2017 |

Specialty Drug List - Sorted by Drug Name
Developed for the Mississippi Division of Medicaid by Mercer

| Therapeutic Class | Drug Brand Name & Strength | Drug Generic Name | Effective Date |
|---------------------------|--------------------------------|--------------------------------|----------------|
| IMMUNE DEFICIENCY | OCTAGAM 10% VIAL | immun globG(IgG)/malt/IgA ov50 | 4/1/2017 |
| IMMUNE DEFICIENCY | OCTAGAM 5% VIAL | immun globG(IgG)/malt/IgA ov50 | 4/1/2017 |
| ONCOLOGY - ORAL | ODOMZO 200 MG CAPSULE | sonidegib phosphate | 4/1/2017 |
| PULMONARY | OFEV 100 MG CAPSULE | nintedanib esylate | 4/1/2017 |
| PULMONARY | OFEV 150 MG CAPSULE | nintedanib esylate | 4/1/2017 |
| PULMONARY HYPERTENSION | OPSUMIT 10 MG TABLET | macitentan | 4/1/2017 |
| ANTI-INFECTIVE | ORBACTIV 400 MG VIAL | oritavancin diphosphate | 4/1/2017 |
| PULMONARY HYPERTENSION | ORENITRAM ER 0.125 MG TABLET | treprostinil diolamine | 4/1/2017 |
| PULMONARY HYPERTENSION | ORENITRAM ER 0.25 MG TABLET | treprostinil diolamine | 4/1/2017 |
| PULMONARY HYPERTENSION | ORENITRAM ER 1 MG TABLET | treprostinil diolamine | 4/1/2017 |
| PULMONARY HYPERTENSION | ORENITRAM ER 2.5 MG TABLET | treprostinil diolamine | 4/1/2017 |
| PULMONARY HYPERTENSION | ORENITRAM ER 5 MG TABLET | treprostinil diolamine | 10/1/2017 |
| ENZYME DEFICIENCY | ORFADIN 10 MG CAPSULE | nitisinone | 4/1/2017 |
| ENZYME DEFICIENCY | ORFADIN 2 MG CAPSULE | nitisinone | 4/1/2017 |
| ENZYME DEFICIENCY | ORFADIN 20 MG CAPSULE | nitisinone | 4/1/2017 |
| ENZYME DEFICIENCY | ORFADIN 4 MG/ML SUSPENSION | nitisinone | 4/1/2017 |
| ENZYME DEFICIENCY | ORFADIN 5 MG CAPSULE | nitisinone | 4/1/2017 |
| PULMONARY | ORKAMBI 100 MG-125 MG TABLET | lumacaftor/ivacaftor | 4/1/2017 |
| PULMONARY | ORKAMBI 100-125 MG GRANULE PKT | lumacaftor/ivacaftor | 10/1/2018 |
| PULMONARY | ORKAMBI 150-188 MG GRANULE PKT | lumacaftor/ivacaftor | 10/1/2018 |
| PULMONARY | ORKAMBI 200 MG-125 MG TABLET | lumacaftor/ivacaftor | 4/1/2017 |
| OTHER SPECIALTY CONDITION | OXBRYTA 500 MG TABLET | voxelotor | 2/1/2020 |
| ENZYME DEFICIENCY | PALYNZIQ 10 MG/0.5 ML SYRINGE | pegvaliase-pqpz | 8/1/2018 |
| ENZYME DEFICIENCY | PALYNZIQ 2.5 MG/0.5 ML SYRINGE | pegvaliase-pqpz | 8/1/2018 |
| ENZYME DEFICIENCY | PALYNZIQ 20 MG/ML SYRINGE | pegvaliase-pqpz | 8/1/2018 |
| ANTI-INFECTIVE | PENTAM 300 VIAL | pentamidine isethionate | 4/1/2017 |
| ONCOLOGY - ORAL | PIQRAY 200 MG DAILY DOSE | alpelisib | 8/1/2019 |
| ONCOLOGY - ORAL | PIQRAY 250 MG DAILY DOSE | alpelisib | 8/1/2019 |
| ONCOLOGY - ORAL | PIQRAY 300 MG DAILY DOSE | alpelisib | 8/1/2019 |
| ONCOLOGY - ORAL | POMALYST 1 MG CAPSULE | pomalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | POMALYST 2 MG CAPSULE | pomalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | POMALYST 3 MG CAPSULE | pomalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | POMALYST 4 MG CAPSULE | pomalidomide | 4/1/2017 |
| OTHER SPECIALTY CONDITION | PREVYMIS 240 MG TABLET | letermovir | 2/1/2018 |
| OTHER SPECIALTY CONDITION | PREVYMIS 240 MG/12 ML VIAL | letermovir | 2/1/2018 |
| OTHER SPECIALTY CONDITION | PREVYMIS 480 MG TABLET | letermovir | 2/1/2018 |
| OTHER SPECIALTY CONDITION | PREVYMIS 480 MG/24 ML VIAL | letermovir | 2/1/2018 |
| IMMUNE DEFICIENCY | PRIVIGEN 10% VIAL | immun glob G(IgG)/pro/IgA 0-50 | 4/1/2017 |
| OTHER SPECIALTY CONDITION | PROCYSBI DR 25 MG CAPSULE | cysteamine bitartrate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | PROCYSBI DR 75 MG CAPSULE | cysteamine bitartrate | 4/1/2017 |
| PULMONARY | PROLASTIN C 1,000 MG/20 ML VL | alpha-1-proteinase inhibitor | 3/1/2018 |
| BLOOD CELL DEFICIENCY | PROMACTA 12.5 MG SUSPEN PACKET | eltrombopag olamine | 3/1/2019 |
| BLOOD CELL DEFICIENCY | PROMACTA 12.5 MG TABLET | eltrombopag olamine | 4/1/2017 |
| BLOOD CELL DEFICIENCY | PROMACTA 25 MG TABLET | eltrombopag olamine | 4/1/2017 |
| BLOOD CELL DEFICIENCY | PROMACTA 50 MG TABLET | eltrombopag olamine | 4/1/2017 |
| BLOOD CELL DEFICIENCY | PROMACTA 75 MG TABLET | eltrombopag olamine | 4/1/2017 |
| OTHER SPECIALTY CONDITION | RADICAVA 30 MG/100 ML BAG | edaravone | 10/1/2017 |
| OTHER SPECIALTY CONDITION | RAVICTI 1.1 GRAM/ML LIQUID | glycerol phenylbutyrate | 4/1/2017 |
| PULMONARY HYPERTENSION | REMODULIN 1 MG/ML VIAL | treprostinil sodium | 4/1/2017 |
| PULMONARY HYPERTENSION | REMODULIN 10 MG/ML VIAL | treprostinil sodium | 4/1/2017 |
| PULMONARY HYPERTENSION | REMODULIN 2.5 MG/ML VIAL | treprostinil sodium | 4/1/2017 |
| PULMONARY HYPERTENSION | REMODULIN 5 MG/ML VIAL | treprostinil sodium | 4/1/2017 |
| ONCOLOGY - ORAL | REVLIMID 10 MG CAPSULE | lenalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | REVLIMID 15 MG CAPSULE | lenalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | REVLIMID 2.5 MG CAPSULE | lenalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | REVLIMID 20 MG CAPSULE | lenalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | REVLIMID 25 MG CAPSULE | lenalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | REVLIMID 5 MG CAPSULE | lenalidomide | 4/1/2017 |

Specialty Drug List - Sorted by Drug Name
Developed for the Mississippi Division of Medicaid by Mercer

| Therapeutic Class | Drug Brand Name & Strength | Drug Generic Name | Effective Date |
|---------------------------|--------------------------------|-------------------------------|----------------|
| ONCOLOGY - ORAL | ROZLYTREK 100 MG CAPSULE | entrectinib | 10/1/2019 |
| ONCOLOGY - ORAL | ROZLYTREK 200 MG CAPSULE | entrectinib | 10/1/2019 |
| ONCOLOGY - ORAL | RUBRACA 200 MG TABLET | rucaparib camsylate | 4/1/2017 |
| ONCOLOGY - ORAL | RUBRACA 250 MG TABLET | rucaparib camsylate | 4/1/2017 |
| ONCOLOGY - ORAL | RUBRACA 300 MG TABLET | rucaparib camsylate | 4/1/2017 |
| HEREDITARY ANGIOEDEMA | RUCONEST 2,100 UNIT VIAL | C1 esterase inhibitor, recomb | 4/1/2017 |
| OTHER SPECIALTY CONDITION | RUZURGI 10 MG TABLET | amifampridine | 8/1/2019 |
| ONCOLOGY - ORAL | RYDAPT 25 MG CAPSULE | midostaurin | 4/1/2017 |
| OTHER SPECIALTY CONDITION | SABRIL 500 MG POWDER PACKET | vigabatrin | 4/1/2017 |
| OTHER SPECIALTY CONDITION | SABRIL 500 MG TABLET | vigabatrin | 4/1/2017 |
| OTHER SPECIALTY CONDITION | SAMSCA 15 MG TABLET | tolvaptan | 4/1/2017 |
| OTHER SPECIALTY CONDITION | SAMSCA 30 MG TABLET | tolvaptan | 4/1/2017 |
| ENDOCRINE DISORDER | SIGNIFOR 0.3 MG/ML AMPULE | pasireotide diaspartate | 4/1/2017 |
| ENDOCRINE DISORDER | SIGNIFOR 0.6 MG/ML AMPULE | pasireotide diaspartate | 4/1/2017 |
| ENDOCRINE DISORDER | SIGNIFOR 0.9 MG/ML AMPULE | pasireotide diaspartate | 4/1/2017 |
| ENDOCRINE DISORDER | SIGNIFOR LAR 10 MG VIAL | pasireotide pamoate | 11/1/2018 |
| ENDOCRINE DISORDER | SIGNIFOR LAR 20 MG KIT | pasireotide pamoate | 4/1/2017 |
| ENDOCRINE DISORDER | SIGNIFOR LAR 30 MG VIAL | pasireotide pamoate | 11/1/2018 |
| ENDOCRINE DISORDER | SIGNIFOR LAR 40 MG KIT | pasireotide pamoate | 4/1/2017 |
| ENDOCRINE DISORDER | SIGNIFOR LAR 60 MG KIT | pasireotide pamoate | 4/1/2017 |
| ANTI-INFECTIVE | SIVEXTRO 200 MG TABLET | tedizolid phosphate | 4/1/2017 |
| ANTI-INFECTIVE | SIVEXTRO 200 MG VIAL | tedizolid phosphate | 4/1/2017 |
| OTHER SPECIALTY CONDITION | SODIUM PHENYLBUTYRATE POWDE | sodium phenylbutyrate | 4/1/2017 |
| ENDOCRINE DISORDER | SOMATULINE DEPOT 120 MG/0.5 | lanreotide acetate | 4/1/2017 |
| ENDOCRINE DISORDER | SOMATULINE DEPOT 60 MG/0.2 | lanreotide acetate | 4/1/2017 |
| ENDOCRINE DISORDER | SOMATULINE DEPOT 90 MG/0.3 | lanreotide acetate | 4/1/2017 |
| ENDOCRINE DISORDER | SOMAVERT 10 MG VIAL | pegvisomant | 4/1/2017 |
| ENDOCRINE DISORDER | SOMAVERT 15 MG VIAL | pegvisomant | 4/1/2017 |
| ENDOCRINE DISORDER | SOMAVERT 20 MG VIAL | pegvisomant | 4/1/2017 |
| ENDOCRINE DISORDER | SOMAVERT 25 MG VIAL | pegvisomant | 4/1/2017 |
| ENDOCRINE DISORDER | SOMAVERT 30 MG VIAL | pegvisomant | 4/1/2017 |
| OTHER SPECIALTY CONDITION | STIMATE 1.5 MG/ML NASAL SPR | desmopressin acetate | 4/1/2017 |
| ONCOLOGY - ORAL | STIVARGA 40 MG TABLET | regorafenib | 4/1/2017 |
| ENZYME DEFICIENCY | STRENSIQ 18 MG/0.45 ML VIAL | asfotase alfa | 4/1/2017 |
| ENZYME DEFICIENCY | STRENSIQ 28 MG/0.7 ML VIAL | asfotase alfa | 4/1/2017 |
| ENZYME DEFICIENCY | STRENSIQ 40 MG/ML VIAL | asfotase alfa | 4/1/2017 |
| ENZYME DEFICIENCY | STRENSIQ 80 MG/0.8 ML VIAL | asfotase alfa | 4/1/2017 |
| PULMONARY | SYMDEKO 100/150 MG-150 MG TABS | tezacaftor/ivacaftor | 4/1/2018 |
| PULMONARY | SYMDEKO 50/75 MG-75 MG TABLETS | tezacaftor/ivacaftor | 9/1/2019 |
| RSV PREVENTION | SYNAGIS 100 MG/1 ML VIAL | palivizumab | 4/1/2017 |
| RSV PREVENTION | SYNAGIS 50 MG/0.5 ML VIAL | palivizumab | 4/1/2017 |
| ANTI-INFECTIVE | SYNERCID 500 MG VIAL | quinupristin/dalfopristin | 4/1/2017 |
| OTHER SPECIALTY CONDITION | SYPRINE 250 MG CAPSULE | trientine HCl | 4/1/2017 |
| ONCOLOGY - ORAL | TABLOID 40 MG TABLET | thioguanine | 4/1/2017 |
| ONCOLOGY - ORAL | TAFINLAR 50 MG CAPSULE | dabrafenib mesylate | 4/1/2017 |
| ONCOLOGY - ORAL | TAFINLAR 75 MG CAPSULE | dabrafenib mesylate | 4/1/2017 |
| ONCOLOGY - ORAL | TAGRISSO 40 MG TABLET | osimertinib mesylate | 4/1/2017 |
| ONCOLOGY - ORAL | TAGRISSO 80 MG TABLET | osimertinib mesylate | 4/1/2017 |
| HEREDITARY ANGIOEDEMA | TAKHZYRO 300 MG/2 ML VIAL | lanadelumab-flyo | 11/1/2018 |
| ONCOLOGY - ORAL | TALZENNA 0.25 MG CAPSULE | talazoparib tosylate | 1/1/2019 |
| ONCOLOGY - ORAL | TALZENNA 1 MG CAPSULE | talazoparib tosylate | 1/1/2019 |
| ONCOLOGY - ORAL | TARCEVA 100 MG TABLET | erlotinib HCl | 4/1/2017 |
| ONCOLOGY - ORAL | TARCEVA 150 MG TABLET | erlotinib HCl | 4/1/2017 |
| ONCOLOGY - ORAL | TARCEVA 25 MG TABLET | erlotinib HCl | 4/1/2017 |
| ONCOLOGY - ORAL | TARGRETIN 75 MG CAPSULE | bexarotene | 4/1/2017 |
| ONCOLOGY - ORAL | TASIGNA 150 MG CAPSULE | nilotinib HCl | 4/1/2017 |
| ONCOLOGY - ORAL | TASIGNA 200 MG CAPSULE | nilotinib HCl | 4/1/2017 |
| ONCOLOGY - ORAL | TASIGNA 50 MG CAPSULE | nilotinib HCl | 6/1/2018 |

Specialty Drug List - Sorted by Drug Name
Developed for the Mississippi Division of Medicaid by Mercer

| Therapeutic Class | Drug Brand Name & Strength | Drug Generic Name | Effective Date |
|----------------------------|------------------------------|--------------------------------|----------------|
| OTHER SPECIALTY CONDITION | TAVALISSE 100 MG TABLET | fostamatinib disodium | 7/1/2018 |
| OTHER SPECIALTY CONDITION | TAVALISSE 150 MG TABLET | fostamatinib disodium | 7/1/2018 |
| ONCOLOGY - ORAL | THALOMID 100 MG CAPSULE | thalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | THALOMID 150 MG CAPSULE | thalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | THALOMID 200 MG CAPSULE | thalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | THALOMID 50 MG CAPSULE | thalidomide | 4/1/2017 |
| ONCOLOGY - ORAL | TIBSOVO 250 MG TABLET | ivosidenib | 1/1/2019 |
| PULMONARY | TOBI PODHALER 28 MG INHALE | tobramycin | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | TOTECT 500 MG VIAL | dexrazoxane HCl | 10/1/2017 |
| PULMONARY HYPERTENSION | TRACLEER 125 MG TABLET | bosentan | 4/1/2017 |
| PULMONARY HYPERTENSION | TRACLEER 32 MG TABLET | bosentan | 1/1/2018 |
| PULMONARY HYPERTENSION | TRACLEER 62.5 MG TABLET | bosentan | 4/1/2017 |
| ONCOLOGY - ORAL | TRETINOIN 10 MG CAPSULE | tretinoin | 4/1/2017 |
| PULMONARY | TRIKAFTA 100/50/75 MG-150 MG | elexacaftor/tezacaftor/ivacaft | 1/1/2020 |
| OTHER SPECIALTY CONDITION | TRIPTODUR | triptorelin pamoate | 11/1/2017 |
| OTHER SPECIALTY CONDITION | TROGARZO 200 MG/1.33 ML VIAL | ibalizumab-uiyk | 6/1/2018 |
| ONCOLOGY - ORAL | TURALIO 200 MG CAPSULE | pexidartinib hydrochloride | 10/1/2019 |
| ONCOLOGY - ORAL | TYKERB 250 MG TABLET | lapatinib ditosylate | 4/1/2017 |
| PULMONARY HYPERTENSION | TYVASO 1.74 MG/2.9 ML SOLUT | treprostinil | 4/1/2017 |
| PULMONARY HYPERTENSION | TYVASO INHALATION REFILL KI | treprostinil/neb accessories | 4/1/2017 |
| PULMONARY HYPERTENSION | TYVASO INHALATION STARTER K | treprostinil/nebulizer/accesor | 4/1/2017 |
| PULMONARY HYPERTENSION | UPTRAVI 1,000 MCG TABLET | selexipag | 4/1/2017 |
| PULMONARY HYPERTENSION | UPTRAVI 1,200 MCG TABLET | selexipag | 4/1/2017 |
| PULMONARY HYPERTENSION | UPTRAVI 1,400 MCG TABLET | selexipag | 4/1/2017 |
| PULMONARY HYPERTENSION | UPTRAVI 1,600 MCG TABLET | selexipag | 4/1/2017 |
| PULMONARY HYPERTENSION | UPTRAVI 200 MCG TABLET | selexipag | 4/1/2017 |
| PULMONARY HYPERTENSION | UPTRAVI 200-800 TITRATION P | selexipag | 4/1/2017 |
| PULMONARY HYPERTENSION | UPTRAVI 400 MCG TABLET | selexipag | 4/1/2017 |
| PULMONARY HYPERTENSION | UPTRAVI 600 MCG TABLET | selexipag | 4/1/2017 |
| PULMONARY HYPERTENSION | UPTRAVI 800 MCG TABLET | selexipag | 4/1/2017 |
| OTHER SPECIALTY CONDITION | VECAMYL 2.5 MG TABLET | mecamylamine HCl | 4/1/2017 |
| PULMONARY HYPERTENSION | VELETRI 0.5 MG VIAL | epoprostenol sodium (arginine) | 4/1/2017 |
| PULMONARY HYPERTENSION | VELETRI 1.5 MG VIAL | epoprostenol sodium (arginine) | 4/1/2017 |
| ONCOLOGY - ORAL | VENCLEXTA 10 MG TABLET | venetoclax | 4/1/2017 |
| ONCOLOGY - ORAL | VENCLEXTA 100 MG TABLET | venetoclax | 4/1/2017 |
| ONCOLOGY - ORAL | VENCLEXTA 50 MG TABLET | venetoclax | 4/1/2017 |
| ONCOLOGY - ORAL | VENCLEXTA STARTING PACK | venetoclax | 4/1/2017 |
| PULMONARY HYPERTENSION | VENTAVIS 10 MCG/1 ML SOLUTI | iloprost tromethamine | 4/1/2017 |
| PULMONARY HYPERTENSION | VENTAVIS 20 MCG/1 ML SOLUTI | iloprost tromethamine | 4/1/2017 |
| ONCOLOGY - ORAL | VERZENIO 100MG TABLET | abemaciclib | 12/1/2017 |
| ONCOLOGY - ORAL | VERZENIO 150MG TABLET | abemaciclib | 12/1/2017 |
| ONCOLOGY - ORAL | VERZENIO 200 MG TABLET | abemaciclib | 12/1/2017 |
| ONCOLOGY - ORAL | VERZENIO 50 MG TABLET | abemaciclib | 12/1/2017 |
| ANTI-INFECTIVE | VIBATIV 750 MG VIAL | telavancin HCl | 2/1/2018 |
| ONCOLOGY - ORAL | VITRAKVI 100 MG CAPSULE | larotrectinib sulfate | 3/1/2019 |
| ONCOLOGY - ORAL | VITRAKVI 20 MG/ML SOLUTION | larotrectinib sulfate | 3/1/2019 |
| ONCOLOGY - ORAL | VITRAKVI 25 MG CAPSULE | larotrectinib sulfate | 3/1/2019 |
| ONCOLOGY - ORAL | VIZIMPRO 15 MG TABLET | dacomitinib | 12/1/2018 |
| ONCOLOGY - ORAL | VIZIMPRO 30 MG TABLET | dacomitinib | 12/1/2018 |
| ONCOLOGY - ORAL | VIZIMPRO 45 MG TABLET | dacomitinib | 12/1/2018 |
| ONCOLOGY - ORAL | VOTRIENT 200 MG TABLET | pazopanib HCl | 4/1/2017 |
| ENZYME DEFICIENCY | VPRIV 400 UNITS VIAL | velaglucerase alfa | 4/1/2017 |
| OTHER SPECIALTY CONDITION | VYNDAMAX 61 MG CAPSULE | tafamidis | 11/1/2019 |
| OTHER SPECIALTY CONDITION | VYONDYS-53 100 MG/2 ML VIAL | golodirsen | 2/1/2020 |
| ONCOLOGY - ORAL | XALKORI 200 MG CAPSULE | crizotinib | 4/1/2017 |
| ONCOLOGY - ORAL | XALKORI 250 MG CAPSULE | crizotinib | 4/1/2017 |
| OTHER SPECIALTY CONDITION | XIAFLEX 0.9 MG VIAL | collagenase Clostridium hist. | 4/1/2017 |
| ONCOLOGY - ORAL | XOSPATA 40 MG TABLET | gilteritinib fumarate | 2/1/2019 |

Specialty Drug List - Sorted by Drug Name
Developed for the Mississippi Division of Medicaid by Mercer

| Therapeutic Class | Drug Brand Name & Strength | Drug Generic Name | Effective Date |
|----------------------------|--------------------------------|--------------------------------|----------------|
| ONCOLOGY - ORAL | XPOVIO 100 MG ONCE WEEKLY DOSE | selinexor | 9/1/2019 |
| ONCOLOGY - ORAL | XPOVIO 60 MG ONCE WEEKLY DOSE | selinexor | 9/1/2019 |
| ONCOLOGY - ORAL | XPOVIO 80 MG ONCE WEEKLY DOSE | selinexor | 9/1/2019 |
| ONCOLOGY - ORAL | XPOVIO 80 MG TWICE WEEKLY DOSE | selinexor | 9/1/2019 |
| ONCOLOGY - ORAL | XTANDI 40 MG CAPSULE | enzalutamide | 4/1/2017 |
| OTHER SPECIALTY CONDITION | XYREM 500 MG/ML ORAL SOLUTI | sodium oxybate | 4/1/2017 |
| ONCOLOGY - ORAL | YONSA 125 MG TABLET | abiraterone acet,submicronized | 8/1/2018 |
| ENZYME DEFICIENCY | ZAVESCA 100 MG CAPSULE | miglustat | 4/1/2017 |
| ONCOLOGY - ORAL | ZEJULA 100 MG CAPSULE | niraparib tosylate | 4/1/2017 |
| ONCOLOGY - ORAL | ZELBORAF 240 MG TABLET | vemurafenib | 4/1/2017 |
| PULMONARY | ZEMAIRA 1,000 MG VIAL | alpha-1-proteinase inhibitor | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | ZINECARD 250 MG VIAL | dexrazoxane HCl | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | ZINECARD 500 MG VIAL | dexrazoxane HCl | 4/1/2017 |
| OTHER SPECIALTY CONDITION | ZINPLAVA 1,000 MG/40 ML VIA | bezlotoxumab | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | ZOLEDRONIC ACID 4 MG VIAL | zoledronic acid | 6/1/2018 |
| ONCOLOGY - ADJUNCT THERAPY | ZOLEDRONIC ACID 4 MG/100 ML | zoledronic ac/mannitol/0.9NaCl | 4/1/2017 |
| ONCOLOGY - ORAL | ZOLINZA 100 MG CAPSULE | vorinostat | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | ZOMETA 4 MG/100 ML INJECTIO | zoledronic acid/mannitol-water | 4/1/2017 |
| ONCOLOGY - ADJUNCT THERAPY | ZOMETA 4 MG/5 ML VIAL | zoledronic acid | 4/1/2017 |
| ONCOLOGY - ORAL | ZYDELIG 100 MG TABLET | idelalisib | 4/1/2017 |
| ONCOLOGY - ORAL | ZYDELIG 150 MG TABLET | idelalisib | 4/1/2017 |
| ONCOLOGY - ORAL | ZYKADIA 150 MG CAPSULE | ceritinib | 4/1/2017 |
| ONCOLOGY - ORAL | ZYKADIA 150 MG TABLET | ceritinib | 7/1/2019 |